Ascendis Pharma A/S $ 144.27 3.57 (2.54%)
Volume:
108,993
Avg Vol (1m):
157,752
Market Cap $:
6.08 Bil
Enterprise Value $:
5.59 Bil
P/E (TTM):
0.00
P/B:
12.97
Financial Strength | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 13.29 | ||
| Equity-to-Asset | 0.85 | ||
| Debt-to-Equity | 0.07 | ||
| Debt-to-EBITDA | -0.15 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 37.33 | ||
| Beneish M-Score | -3.84 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -3277.5 | ||
| Net Margin % | -3148.66 | ||
| ROE % | -44.55 | ||
| ROA % | -39.22 | ||
| ROC (Joel Greenblatt) % | -547.49 | ||
| 3-Year Revenue Growth Rate | 20.5 | ||
| 3-Year EBITDA Growth Rate | -23 | ||
| 3-Year EPS without NRI Growth Rate | -24.2 |
ASND
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 12.97 | ||
| PS Ratio | 739.86 | ||
| EV-to-EBIT | -19.86 | ||
| EV-to-EBITDA | -20.54 | ||
| EV-to-Revenue | 598.82 | ||
| Current Ratio | 9.04 | ||
| Quick Ratio | 9.04 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 13.08 | ||
| Earnings Yield (Greenblatt) % | -5.04 |